BioAffinity Technologies, EBITDA vs. Shares Owned By Institutions
| BIAF Stock | USD 1.22 0.05 4.27% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -7.6 M | Current Value -8 M | Quarterly Volatility 1.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.3 | 0.3126 |
|
|
For BioAffinity Technologies, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioAffinity Technologies, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well bioAffinity Technologies, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioAffinity Technologies,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of bioAffinity Technologies, over time as well as its relative position and ranking within its peers.
BioAffinity |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.744 | Quarterly Revenue Growth 120.474 | Return On Assets (0.70) | Return On Equity (1.52) |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
bioAffinity Technologies, Shares Owned By Institutions vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioAffinity Technologies,'s current stock value. Our valuation model uses many indicators to compare BioAffinity Technologies, value to that of its competitors to determine the firm's financial worth. bioAffinity Technologies, is rated fifth in ebitda category among its peers. It is rated below average in shares owned by institutions category among its peers . At this time, BioAffinity Technologies,'s EBITDA is most likely to decrease significantly in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value BioAffinity Technologies, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.BioAffinity Shares Owned By Institutions vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
BioAffinity Technologies, |
| = | (7.63 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
BioAffinity Technologies, |
| = | 2.46 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
BioAffinity Shares Owned By Institutions Comparison
BioAffinity Technologies, is currently under evaluation in shares owned by institutions category among its peers.
BioAffinity Technologies, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioAffinity Technologies,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioAffinity Technologies, will eventually generate negative long term returns. The profitability progress is the general direction of BioAffinity Technologies,'s change in net profit over the period of time. It can combine multiple indicators of BioAffinity Technologies,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3.6 M | -3.8 M | |
| Operating Income | -8 M | -7.6 M | |
| Income Before Tax | -7.9 M | -8.3 M | |
| Total Other Income Expense Net | 57.2 K | 60.1 K | |
| Net Loss | -7.9 M | -8.3 M | |
| Income Tax Expense | 21 K | 22 K | |
| Net Interest Income | 47.3 K | 49.7 K | |
| Interest Income | 148.4 K | 155.8 K | |
| Net Loss | -7.2 M | -7.6 M | |
| Net Loss | -7.3 M | -7.6 M | |
| Change To Netincome | 2.8 M | 3.1 M | |
| Net Loss | (0.91) | (0.95) | |
| Income Quality | 0.76 | 0.42 | |
| Net Income Per E B T | 1.00 | 0.80 |
BioAffinity Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioAffinity Technologies,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioAffinity Technologies, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioAffinity Technologies,'s important profitability drivers and their relationship over time.
Use BioAffinity Technologies, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioAffinity Technologies, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioAffinity Technologies, will appreciate offsetting losses from the drop in the long position's value.BioAffinity Technologies, Pair Trading
bioAffinity Technologies, Pair Trading Analysis
The ability to find closely correlated positions to BioAffinity Technologies, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioAffinity Technologies, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioAffinity Technologies, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling bioAffinity Technologies, to buy it.
The correlation of BioAffinity Technologies, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioAffinity Technologies, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if bioAffinity Technologies, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioAffinity Technologies, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioAffinity Technologies, position
In addition to having BioAffinity Technologies, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investor Favorites Thematic Idea Now
Investor Favorites
Macroaxis most traded equities with largest long positions over the last 2 years. The Investor Favorites theme has 21 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investor Favorites Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project BioAffinity Technologies,'s future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of bioAffinity Technologies, at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioAffinity Technologies,'s income statement, its balance sheet, and the statement of cash flows.